Participate in a Groundbreaking Non-Invasive Imaging Trial
A diagnosis of HR-/HER2+ breast cancer can be scary, and identifying the right course of action is overwhelming. That’s why research is so important!
BAMF Health is at the forefront of research. We are launching a non-invasive imaging clinical trial for those with HR-/HER2+ metastatic breast cancer. This trial aims to understand the prevalence of a specific biomarker in this subset of breast cancer. We invite you to apply.
Women with breast cancer deserve more options—help us get there faster.
Eligibility and Benefits
Eligibility Criteria
- At least 18 years old
- Diagnosed with HR-/HER2+ metastatic breast cancer
- At least one measurable tumor lesion on conventional imaging
- Women of childbearing potential must have a negative pregnancy test
Benefits to Participating
- Receive an advanced PET scan at BAMF Health
- Images will be sent to your doctor
- $500 stipend provided
- The opportunity to advance options for women diagnosed with breast cancer
Let's Advance Research Together!
BAMF Health Clinical Trial Updates
BAMF Health, Ferris State, KentISD expand partnership to accelerate high schoolers’ path toward innovative STEM careers
Enrollment for this year’s FutureSolve program is nearly double last year’s.
July 6, 2025
BAMF Health Launches National Clinical Trials Platform, BAMF RadioNexus, and Enrolls National Health System
RadioNexus is the world’s first radiopharmaceutical-focused clinical trials network.
June 18, 2025
BAMF Health Doses First Patient in the U.S. in Phase 2b Imaging Study of Brain Metastasis
BAMF Health dosed the first patient in the U.S. for Radiopharm Theranostics’ Phase 2b imaging study of 18F-RAD101 in suspected recurrent brain metastasis.
April 28, 2025